The role of corticosteroids in muscular dystrophy

A critical appraisal

Corrado Angelini

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Over the years various steroid trials have been conducted in Duchenne muscular dystrophy (DMD). In children who are still able to walk as well as in those who are wheelchair-bound, corticosteroids have been found to stabilize muscle strength for a period of time. Controlled clinical observations have shown that some boys remain ambulatory for years longer than reported in natural history data. The two main steroids used are prednisone/prednisolone and deflazacort. They are probably equally effective in stabilizing muscle strength but may have different side-effect profiles; for instance, deflazacort causes less weight gain. The exact mechanism by which steroids slow the dystrophic process is under investigation. DMD children treated long term also seem to develop other complications of the condition less frequently. For instance, they develop respiratory insufficiency later and have fewer cardiac symptoms. The therapeutic value of corticosteroids is limited, but these drugs represent the best treatment option currently available.

Original languageEnglish
Pages (from-to)424-435
Number of pages12
JournalMuscle and Nerve
Volume36
Issue number4
DOIs
Publication statusPublished - Oct 2007

Fingerprint

Muscular Dystrophies
Adrenal Cortex Hormones
Duchenne Muscular Dystrophy
Steroids
Muscle Strength
Wheelchairs
Prednisone
Prednisolone
Natural History
Respiratory Insufficiency
Weight Gain
Therapeutics
Pharmaceutical Preparations
deflazacort

Keywords

  • Deflazacort
  • Duchenne muscular dystrophy
  • Functional outcome
  • Prednisolone
  • Prednisone
  • Respiratory insufficiency
  • Steroids
  • Trials
  • Weakness

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

The role of corticosteroids in muscular dystrophy : A critical appraisal. / Angelini, Corrado.

In: Muscle and Nerve, Vol. 36, No. 4, 10.2007, p. 424-435.

Research output: Contribution to journalArticle

Angelini, Corrado. / The role of corticosteroids in muscular dystrophy : A critical appraisal. In: Muscle and Nerve. 2007 ; Vol. 36, No. 4. pp. 424-435.
@article{a36fd7552b2a440b9b108a3f205a398a,
title = "The role of corticosteroids in muscular dystrophy: A critical appraisal",
abstract = "Over the years various steroid trials have been conducted in Duchenne muscular dystrophy (DMD). In children who are still able to walk as well as in those who are wheelchair-bound, corticosteroids have been found to stabilize muscle strength for a period of time. Controlled clinical observations have shown that some boys remain ambulatory for years longer than reported in natural history data. The two main steroids used are prednisone/prednisolone and deflazacort. They are probably equally effective in stabilizing muscle strength but may have different side-effect profiles; for instance, deflazacort causes less weight gain. The exact mechanism by which steroids slow the dystrophic process is under investigation. DMD children treated long term also seem to develop other complications of the condition less frequently. For instance, they develop respiratory insufficiency later and have fewer cardiac symptoms. The therapeutic value of corticosteroids is limited, but these drugs represent the best treatment option currently available.",
keywords = "Deflazacort, Duchenne muscular dystrophy, Functional outcome, Prednisolone, Prednisone, Respiratory insufficiency, Steroids, Trials, Weakness",
author = "Corrado Angelini",
year = "2007",
month = "10",
doi = "10.1002/mus.20812",
language = "English",
volume = "36",
pages = "424--435",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - The role of corticosteroids in muscular dystrophy

T2 - A critical appraisal

AU - Angelini, Corrado

PY - 2007/10

Y1 - 2007/10

N2 - Over the years various steroid trials have been conducted in Duchenne muscular dystrophy (DMD). In children who are still able to walk as well as in those who are wheelchair-bound, corticosteroids have been found to stabilize muscle strength for a period of time. Controlled clinical observations have shown that some boys remain ambulatory for years longer than reported in natural history data. The two main steroids used are prednisone/prednisolone and deflazacort. They are probably equally effective in stabilizing muscle strength but may have different side-effect profiles; for instance, deflazacort causes less weight gain. The exact mechanism by which steroids slow the dystrophic process is under investigation. DMD children treated long term also seem to develop other complications of the condition less frequently. For instance, they develop respiratory insufficiency later and have fewer cardiac symptoms. The therapeutic value of corticosteroids is limited, but these drugs represent the best treatment option currently available.

AB - Over the years various steroid trials have been conducted in Duchenne muscular dystrophy (DMD). In children who are still able to walk as well as in those who are wheelchair-bound, corticosteroids have been found to stabilize muscle strength for a period of time. Controlled clinical observations have shown that some boys remain ambulatory for years longer than reported in natural history data. The two main steroids used are prednisone/prednisolone and deflazacort. They are probably equally effective in stabilizing muscle strength but may have different side-effect profiles; for instance, deflazacort causes less weight gain. The exact mechanism by which steroids slow the dystrophic process is under investigation. DMD children treated long term also seem to develop other complications of the condition less frequently. For instance, they develop respiratory insufficiency later and have fewer cardiac symptoms. The therapeutic value of corticosteroids is limited, but these drugs represent the best treatment option currently available.

KW - Deflazacort

KW - Duchenne muscular dystrophy

KW - Functional outcome

KW - Prednisolone

KW - Prednisone

KW - Respiratory insufficiency

KW - Steroids

KW - Trials

KW - Weakness

UR - http://www.scopus.com/inward/record.url?scp=34848840925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848840925&partnerID=8YFLogxK

U2 - 10.1002/mus.20812

DO - 10.1002/mus.20812

M3 - Article

VL - 36

SP - 424

EP - 435

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 4

ER -